Motor protein function in skeletal abdominal muscle of cachectic cancer patients

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 1, 2014, Pages 69-79

  Taskin, Sultan ^a   Stumpf, Vera Isabell ^a   Bachmann, Jeannine ^b   Weber, Cornelia ^a   Martignoni, Marc Eric ^b   Friedrich, Oliver ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cancer; Contractility; Motility assay; Muscle cachexia; Myosin isoforms

Indexed keywords

ANIMALIA;

CALCIUM; ISOPROTEIN; MYOSIN; UBIQUITIN;

ABDOMINAL WALL MUSCULATURE; ADULT; AGED; ARTICLE; CACHEXIA; COLON TUMOR; FEMALE; HUMAN; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; MOTILITY ASSAY; MUSCLE CACHEXIA; MUSCLE CONTRACTILITY; MUSCLE CONTRACTION; MYOSIN ISOFORMS; NEOPLASM; PANCREAS TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SINGLE CELL ANALYSIS; VERY ELDERLY;

CANCER; CONTRACTILITY; MOTILITY ASSAY; MUSCLE CACHEXIA; MYOSIN ISOFORMS;

ABDOMINAL MUSCLES; ADULT; AGED; AGED, 80 AND OVER; CACHEXIA; CALCIUM; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MYOSINS; PANCREATIC NEOPLASMS; PROTEIN ISOFORMS; SINGLE-CELL ANALYSIS; UBIQUITIN;

EID: 84891373166     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12165     Document Type: Article

References (60)

1. Tisdale MJ. Mechanisms of cancer cachexia. Phys Rev. 2009; 89: 381-410.
2. Fortunati N, Manti R, Birocco N, et al. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol Rep. 2007; 18: 1521-7.
3. Cai D, Frantz JD, Tawa NE Jr, et al. IKKbeta/NFkappaB activation causes severe muscle wasting in mice. Cell. 2004; 119: 285-98.
4. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, et al. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008; 12: 1193-201.
5. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002; 2: 862-71.
6. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12: 489-95.
7. Baltgalvis KA, Berger FG, Pena MM, et al. Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice. J Appl Physiol. 2010; 109: 1155-61.
8. 2+ activation of force generation in single human skeletal muscle fibres. Exp Physiol. 2008; 93: 486-95.
9. Khamoui AV, Kim JS. Candidate mechanisms underlying effects of contractile activity on muscle morphology and energetic in cancer cachexia. Eur J Cancer Care (Engl.). 2012; 21: 143-57.
10. Penna F, Bonetto A, Muscaritol M, et al. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? Int J Cancer. 2010; 127: 1706-17.
11. Bonetto A, Aydogdu T, Kunzevitzky N, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE. 2011; 6: e22538.
12. Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012; 16: 153-66.
13. Costelli P, Refo P, Penna F, et al. Ca(2+) dependent proteolysis in muscle wasting. Int J Biochem Cell Biol. 2005; 37: 2134-46.
14. Costelli P, Tullio RD, Baccino FM, et al. Activation of Ca(2+) dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer. 2001; 84: 946-50.
15. Busquets S, Garcia-Martinez C, Alvarez B, et al. Calpain-3 gene expression is decreased during experimental cancer cachexia. Biochim Biophys Acta. 2000; 1475: 5-9.
16. Temparis S, Asensi M, Taillandier D, et al. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res. 1994; 54: 5568-73.
17. Baracos VE, DeVivo C, Hoyle DH, et al. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995; 268: E996-1006.
18. Khal J, Wyke SM, Russel ST, et al. Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br J Cancer. 2005; 93: 774-80.
19. Reid MB. Response of the ubiquitin-proteasome pathway to changes in muscle activity. Am J Physiol Regul Integr Comp Physiol. 2005; 288: R1423-31.
20. Costelli P, Bossola M, Muscaritoli M, et al. Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+) dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine. 2002; 19: 1-5.
21. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Com Physiol. 2001; 280: R1518-23.
22. DeJong CH, Busquets S, Moses AG, et al. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol Rep. 2005; 14: 257-63.
23. Jatoi A, Cleary MP, Tee CM, et al. Weight gain does not preclude increased ubiquitin conjugation in skeletal muscle: an exploratory study in tumor-bearing mice. Ann Nutr Metab. 2000; 45: 116-20.
24. Xu P, Peng J. Characterization of polyubiquitin chain structure by middle-down mass spectrometry. Anal Chem. 2008; 80: 3438-44.
25. Li W, Ye Y. Polyubiquitin chains: functions, structures and mechanisms. Cell Mol Life Sci. 2008; 65: 2397-406.
26. Wilkinson KD, Ventii KH, Friedrich KL, et al. The ubiquitin signal: assembly, recognition and termination. Symposium on ubiquitin and signaling. EMBO Rep. 2005; 6: 815-20.
27. Trempe JF. Reading the ubiquitin postal code. Curr Opin Struct Biol. 2011; 21: 792-801.
28. Thrower JS, Hoffman L, Rechsteiner M, et al. Recognition of the polyubiquitin proteolytic signal. EMBO J. 2000; 19: 94-102.
29. Toledo M, Busquets S, Sirisi S, et al. Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncol Rep. 2011; 25: 183-93.
30. Gorselink M, Vaessen SFC, Van Der Flier LG, et al. Mass-dependent decline of skeletal muscle function in cancer cachexia. Muscle Nerve. 2006; 33: 691-3.
31. Murphy KT, Chee A, Gleeson BG, et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol. 2011; 301: R716-26.
32. Weber MA, Krakowski-Roosen H, Schröder L, et al. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 2009; 48: 116-24.
33. Banduseela V, Ochala J, Lamberg K, et al. Muscle paralysis and myosin loss in a patient with cancer cachexia. Acta Myologica. 2007; 26: 136-44.
34. Toth MJ, Miller MS, Callahan DM, et al. Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics. J Appl Physiol. 2013; 114: 858-68.
35. Norman K, Stobaeus N, Smoliner C, et al. Determinants of hand grip strength, knee extension strength and functional status in cancer patients. Clin Nutr. 2010; 29: 586-91.
36. Galvao DA, Taaffe DR, Spry N, et al. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2009; 12: 198-203.
37. Friedrich O, Hund E, Weber C, et al. Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol. 2004; 251: 53-65.
38. Höök P, Larsson L. Actomyosin interactions in a novel single muscle fiber in vitro motility assay. J Muscle Res Cell Motil. 2000; 21: 357-65.
39. von Wegner F, Ober T, Weber C, et al. Velocity distributions of single F-actin trajectories from fluorescence image series using trajectory reconstruction and optical flow mapping. J Biomed Opt. 2008; 13: 054018.
40. Friedrich O, Both M, Weber C, et al. Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle. Biophys J. 2010; 98: 606-16.
41. Agbulut O, Li Z, Mouly V, et al. Analysis of skeletal and cardiac muscle from desmin knock-out and normal mice by high resolution separation of myosin heavy-chain isoforms. Biol Cell. 1996; 88: 131-5.
42. Weeds AG. Light chains from slow-twitch muscle myosin. Eur J Biochem. 1976; 66: 157-73.
43. Larsson L, Moss RL. Maximum velocity of shortening in relation to myosin isoforms composition in single fibres from human skeletal muscles. J Physiol. 1993; 472: 595-614.
44. Sosnicki AA, Lutz GJ, Rome LC, et al. Histochemical and molecular determination of fiber types in chemically skinned single equine skeletal muscle fibers. J Histochem Cytochem. 1989; 37: 1731-8.
45. Mollica JP, Oakhill JS, Lamb GD, et al. Are genuine changes in protein expression being overlooked? Reassessing Western blotting Anal Biochem. 2009; 386: 270-5.
46. Sparkman DR, Hill SJ, White CL. A rapid one-step extraction procedure for the isolation of ubiquitin from human erythrocytes for antibody production. Prep Biochem. 1991; 21: 93-104.
47. Reggiani C, Potma EJ, Bottinelli R, et al. Chemo-mechanical energy transduction in relation to myosin isoform composition in skeletal muscle fibres of the rat. J Physiol. 1997; 502: 449-60.
48. Stevens L, Firinga C, Gohlsch B, et al. Effects of unweighting and clenbuterol on myosin light and heavy chains in fast and slow muscles of the rat. Am J Physiol Cell Physiol. 2000; 279: C1558-63.
49. Tisdale MJ. Molecular pathways leading to cancer cachexia. Physiology. 2005; 20: 340-8.
50. Schneemilch CE, Ittenson A, Ansorge S, et al. Effect of 2 anesthetic techniques on the postoperative proinflammatory and anti-inflammatory cytokine response and cellular immune function to minor surgery. J Clin Anesth. 2005; 17: 517-27.
51. Ortega-Deballon P, Radais F, Facy O, et al. C-reactive protein is an early predictor of septic complications after elective colorectal surgery. World J Surg. 2010; 34: 808-14.
52. 2+] transient in fast-twitch fibers of mouse muscle. J Gen Physiol. 1996; 108: 455-69.
53. Bottinelli R, Pellegrino MA, Canepari M, et al. Specific contributions of various muscle fibre types to human muscle performance: an in vitro study. J Electromyogr Kinesiol. 1999; 9: 87-95.
54. 2+ sensitivity of fast and slow monkey skeletal muscle fibers. J Appl Physiol. 1998; 84: 1776-87.
55. Diffee GM, Kalfas K, Al-Majid S, et al. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol. 2002; 283: C1376-82.
56. Greenberg MJ, Mealy TR, Jones M, et al. The direct molecular effects of fatigue and myosin regulatory light chain phosphorylation on the actomyosin contractile apparatus. Am J Physiol Regul Integr Comp Physiol. 2010; 298: R989-96.
57. Op den Kamp CM, Langen RC, Minnard R, et al. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. 2012; 76: 112-7.
58. Ponelies N, Gosenca D, Ising N, et al. Effects on the ubiquitin proteasome system after closed soft-tissue trauma in rat skeletal muscle. Eur J Trauma Emerg Surg. 2011; 37: 645-54.
59. Vermaelen M, Marini JF, Choprad A, et al. Ubiquitin targeting of rat muscle proteins during short periods of unloading. Acta Physiol Scand. 2005; 185: 33-40.
60. Tiao G, Fagan JM, Samuels N, et al. Sepsis stimulates nonlysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle. J Clin Invest. 1994; 94: 2255-64.